Screener
Capricor Therapeutics CAPR Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| Line item | March 31, 2026 / (unaudited) | December 31, 2025 | December 31, 2025 |
|---|---|---|---|
| Accrued expenses | 10,528,351 | 15,557,646 | |
| Lease liabilities, current | 841,135 | 202,376 | |
| CIRM liability, current | 6,339,862 | 6,421,984 | |
| Deferred revenue, current | 12,000,000 | 12,000,000 | |
| TOTAL CURRENT LIABILITIES | 33,637,289 | 35,836,760 | |
| LONG-TERM LIABILITIES | |||
| Lease liabilities, net of current | 13,943,595 | 14,320,389 | |
| TOTAL LONG-TERM LIABILITIES | 13,943,595 | 14,320,389 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's deferred revenue?
- Capricor Therapeutics (CAPR) reported deferred revenue of $12M in Q1 2026.
- How has Capricor Therapeutics's deferred revenue changed year-over-year?
- Capricor Therapeutics's deferred revenue decreased by 0.0% year-over-year, from $12M to $12M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Capricor Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude